期刊文献+

新型载阿霉素纳米粒子制备及其性能研究 被引量:1

New doxorubicin nanoparticle preparation and its performance study
原文传递
导出
摘要 目的制备新型载阿霉素纳米粒子,观察其理化性能,研究其对乳腺癌MDA-MB231细胞凋亡及在裸鼠体内的抑瘤作用,为三阴性乳腺癌的治疗提供依据。方法制备右旋糖苷纳米粒子,构建EGFR-Dextran-DOX纳米材料,Hoechst33258荧光染料及ELISA实验检测MDA-MB231细胞凋亡。将裸鼠随机分为4组,作相应处理后分别注射磷酸缓冲盐溶液(PBS)、阿霉素(DOX)、Dextran-DOX及EGFR-Dextran-DOX,测量各组瘤体大小。结果 EGFR-DextranDOX纳米粒子大小均一,平均粒径98 nm,包封率为77.0%,载药量9.8%。pH值越低,EGFR-Dextran-DOX纳米粒子DOX释放率越高。EGFR-Dextran-DOX处理组的细胞凋亡率及在裸鼠体内的抑瘤作用高于DOX和Dextran-DOX组,差异有统计学意义(P<0.05)。结论成功制备EGFR-Dextran-DOX纳米粒子,制备的纳米粒对三阴性乳腺癌具有靶向抑制作用。 Objective To develop a new doxorubicin loaded nanoparticle and observe its physical properties,research its apoptosis of breast cancer MDA-MB231 cells and tumor suppression in nude mice, thus in this way to provide a new basis for triple negative breast cancer (TNBC) treatment. Methods Dextran nanoparticles were prepared in the first place then we established EGFR-Dextran-DOX nanoparticle,and detected MDA-MB231 cell apoptosis with Hoechst33258 fluorescence dye and ELISA, then randomly divided 24 nude mice into 4 groups.After corresponding treatment, different drugs were given, and the tumor size was measured. Results The average size of dox nanoparticles was 98 nm, encapsulation efficiency and drug loading capacity were 77.0% and 9.8%, respectively.In vitro release of dox nonoparticles , the lower the pH, the higher the release rate of dox.Cell apoptosis rate treated by EGFR-Dextran-DOX was higher than which treated with dox and Dextran-Dox, the same result as tumor suppression effect in nude mice, all of them had statistical meaning (P〈0.05). Conclusion EGFR-Dextran-DOX nanoparticles were successfully developed, which has significant targeted inhibition to TNBC.
出处 《热带医学杂志》 CAS 2016年第1期35-38,F0004,共5页 Journal of Tropical Medicine
基金 广东省科技计划项目(2014A020212038 2013B021800097) 深圳市知识创新计划基础研究项目(JCYJ20150330102720122)
关键词 阿霉素 纳米粒子 三阴性乳腺癌 靶向治疗 Doxorubicin Nanoparticle Triple negative breast cancer Targeted therapy
  • 相关文献

参考文献12

  • 1von Minckwitz G,Martin M.Neoadjuvant treatments for triplenegative breat cancer(TNBC)[J].Ann Oncol,2012,23 Suppl 6:vi35-39.
  • 2Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J].J Clin Oncol,2008,26(8):1275-1281.
  • 3Keam B,Im SA,Kim HJ,et al.Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy:paradoxical features of the triple negative breast cancer[J].BMC Cancer,2007,7:203.
  • 4Franchina T,Adamo B,Ricciardi GR,et al.Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement:two case reports[J].Cancer Biol Ther,2012,13(7):472-476.
  • 5Raguz S,Adams C,Masrour N,et al.Loss of Omethylguanine-DNAmethyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells[J].Biochem Pharmacol,2013,85(2):186-196.
  • 6Bar-Joseph H,Ben-Aharon I,Tzabari M,et al.In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels[J].PLo S One,2011,6(9):e23492.
  • 7Sishi BJ,Loos B,van Rooyen J,et al.Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity[J].Biochem Pharmacol,2013,85(1):124-134.
  • 8Kamaly N,Xiao Z,Valencia PM,et al.Targeted polymeric therapeutic nanoparticles:design,development and clinical translation[J].Chem Soc Rev,2012,41(7):2971-3010.
  • 9Karra N,Benita S.The ligand nanoparticle conjugation approach for targetd cancer therapy[J].Curr Drug Metab 2012,13(1):22-41.
  • 10Davis ME,Chen ZG,Shin DM.Nanoparticle therapeutics:an emerging treatmet modality for cancer[J].Nat Rev Drug Discov,2008,7(9):771-782.

二级参考文献57

  • 1王玉,王东凯,孙念.pH-敏感型纳米制剂概述[J].中国药剂学杂志(网络版),2009(2):72-76. 被引量:2
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA CancerJClin, 2011, 61(2): 69-90.
  • 3Yang Y, Wang H. Perspectives of nanotechnology in minimally invasive therapy of breast cancer[J]. J Healthc Eng, 2013, 4(1): 67-86.
  • 4Tanaka T, Decuzzi P, Cristofanilli M, et al. Nanotechnology for breast cancer therapy[J].BiomedMicrodevices, 2009, 11(1): 49-63.
  • 5Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned[J]. J Control Release , 2012, 160(2): 117-134.
  • 6Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis[J]. Adv Drug Deliv Rev, 2002, 54(5): 631-651.
  • 7Oerlemans C, Bult W, Bos M, et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release[J]. Pharm Res, 2010, 27(12): 2569-2589.
  • 8Senthil KP, Pastoriza-Santos I, Rodriguez-Gonzalez B, et al. High- yield synthesis and optical response of gold nanostars[J]. Nanotechnology,2008, 19(1): 15606.
  • 9Heath JR, Davis ME. Nanotechnology and cancer[J].Annu Rev Med, 2008, 59(9): 251-265.
  • 10Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress[J]. Drug Discov Today, 2004, 9(5): 219-228.

共引文献1

同被引文献10

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部